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Abstract
Background: Frailty is independently associated with worse health-related quality of life (HRQOL) in chronic kidney
disease (CKD). However, the relationship between frailty and symptom experience is not well described in people
living with CKD. This study’s aim was to evaluate the relationship between frailty and symptom-burden in CKD.
Methods: This study is a secondary analysis of a cross-sectional observational study, the QCKD study (ISRC
TN87066351), in which participants completed physical activity, cardiopulmonary fitness, symptom-burden and
HRQOL questionnaires. A modified version of the Frailty Phenotype, comprising 3 self-report components, was
created to assess frailty status. Multiple linear regression was performed to assess the association between
symptom-burden/HRQOL and frailty. Logistic regression was performed to assess the association between
experiencing symptoms frequently and frailty. Principal Component Analysis was used to assess the experienced
symptom clusters.
Results: A total of 353 patients with CKD were recruited with 225 (64%) participants categorised as frail. Frail
participants reported more symptoms, had higher symptom scores and worse HRQOL scores. Frailty was
independently associated with higher total symptom score and lower HRQOL scores. Frailty was also independently
associated with higher odds of frequently experiencing 9 out of 12 reported symptoms. Finally, frail participants
experienced an additional symptom cluster that included loss of appetite, tiredness, feeling cold and poor
concentration.
Conclusions: Frailty is independently associated with high symptom-burden and poor HRQOL in CKD. Moreover,
people living with frailty and CKD have a distinctive symptom experience. Proactive interventions are needed that
can effectively identify and address problematic symptoms to mitigate their impact on HRQOL.
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Background
Improved life-expectancy has been a major success of
modern healthcare. However, with increased longevity
comes an increased prevalence of older individuals
living with multimorbidity. This trend is predicted to
continue with 20.4 million people estimated to be ≥65
years old by 2066 in the UK, compared with 11.8 mil-
lion in 2016 [1]. The fastest increase is predicted to be
in the ≥85-year-old age group [1]. Both ageing and
multimorbidity are associated with frailty, the state of
vulnerability to disproportionate changes in health sta-
tus when exposed to stressor events [2–4]. In Europe,
the prevalence of frailty is reported to be 7.7% and pre-
frailty, the precursor to frailty, 42.9% [3, 5]. Importantly
for nephrology services, the prevalence of frailty
appears to be far greater in those with chronic kidney
disease (CKD) than in the general older population,
with one study reporting a prevalence as high as 73% in
dialysis dependent CKD [6].
There are two principal conceptual models of
frailty, specifically the deficit accumulation model of
frailty and the physical model of frailty [3, 7]. Though
differing in their underlying theories, both predict
vulnerability to adverse outcomes [8]. The physical
model of frailty, often referred to as the Frailty
Phenotype (FP), is described as a clinical syndrome
involving at least three of the following components:
unintentional weight loss, self-reported exhaustion,
weakness (measured by grip strength), slow walking
speed, and low physical activity [3]. It has a robust
evidence base for predicting outcomes in patients
with CKD, including increased falls, hospitalisation
and mortality risk [6, 9].
People with both end-stage kidney disease and earlier
stages of CKD report high symptom-burden that has a
negative influence on health-related quality of life
(HRQOL) [10–14]. Notably, frailty is independently as-
sociated with worse HRQOL in CKD populations
[15–17]. However, the relationship between frailty and
symptom experience is not well described in people liv-
ing with CKD, particularly in earlier stages of CKD.
Older patients and individuals with CKD prioritise out-
comes relevant to daily activities and general well-being,
including symptom management, over prolonged sur-
vival [18–20]. Research is needed to better understand
how living with frailty and CKD influences symptomol-
ogy. Targeted interventions can then be developed that
are able to improve relevant patient-reported outcomes.
The study’s objectives were to: (i) evaluate the relation-
ship between frailty and symptom-burden in CKD; (ii)
establish the most prevalent symptoms experienced by
people with frailty and CKD; and (iii) assess the
symptom-clusters experienced by non-frail and frail
people with CKD.
Methods
Study design, setting and participant selection
This study is a secondary analysis of the QCKD study
data (ISRCTN87066351), which was a cross-sectional
observational study that aimed to improve understand-
ing of physical activity behaviour across CKD stages
[21]. Data presented in this analysis were gathered be-
tween February 2018 and October 2018. Ethical approval
was granted by the East Midlands-Leicester South Re-
search Ethics Committee and Health Research Authority
(reference: 12/EM/0184). Written informed consent was
obtained from all participants and the study was con-
ducted in compliance with the Declaration of Helsinki.
Potential participants were identified from a general
practitioner (GP) practice in the Leicester region, United
Kingdom (UK), and from the Renal Risk in Derby
(RRID) study population [22], which originally recruited
participants from 32 primary care clinics in Derbyshire,
UK. Participants aged ≥18 years old with two estimated
glomerular filtration rate (eGFR) values < 60ml/min/
1.73m2 more than 90 days apart and able to give in-
formed consent were eligible for inclusion.
Outcome measures
Participants were asked to complete a survey pack that
contained study outcome measures. Recruitment was via
two routes: in the GP practice, eligible patients were
identified by practice staff, and participants in the RRID
study, who had previously been recruited from GP prac-
tices [22], were screened by the Chief Investigator and
research staff. In both cases, potential participants were
sent study packs containing an invitation letter and in-
formation sheet, consent form and the survey pack for
completion, together with a post-paid return envelope.
The demographic and clinical characteristics section of
the survey pack asked participants to report their age,
sex, smoking history and highest level of educational at-
tainment. Participants were also asked to report the
presence of health problems. Haemoglobin, eGFR and
albumin laboratory variables were obtained from medical
records with informed consent. The survey pack also
contained the following questionnaires: General Practice
Physical Activity Questionnaire (GPPAQ), Duke Activity
Status Index (DASI), Short Form-12 (SF-12) and Kidney
Symptom Questionnaire (KSQ).
The GPPAQ is a questionnaire developed by the De-
partment of Health to assess levels of physical activity
[23, 24]. The GPPAQ consists of questions about both
work and domestic physical activities and perceived
walking pace. Responses are used to calculate a 4-level
physical activity index reflecting current physical activity.
Participants are categorised as either ‘active’, ‘moderately
active’, ‘moderately inactive’ or ‘inactive’.
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The DASI is a questionnaire that measures functional
capacity [25, 26]. It comprises 12-items that assess
perceived ability to perform activities of daily living.
Responses are used to calculate a raw DASI score, with
higher scores indicating greater functional capacity. As
previously validated [26], scores were transformed into
estimated peak oxygen uptake (VO2 peak) values to pro-
vide a measure of cardiopulmonary fitness.
The SF-12 encompasses 12 questions that are used to
assess HRQOL [11, 27]. Responses can be used to
construct an 8-scale profile of health and well-being and
to generate physical and mental health summary
measures: Physical Component Summary (PCS) and
Mental Component Summary (MCS). Higher scores
represent better HRQOL.
The KSQ is a questionnaire that measures participant
symptom perception [10, 28, 29]. The updated version
was used to assess the frequency of 13 symptoms on a
five-point scale: ‘never’ (0), ‘less than once a week’ (1),
‘1-2 times a week’ (2), ‘several times a week’ (3), or ‘every
day’ (4). The total frequency score was used to assess
total symptom-burden with higher scores denoting
greater symptom-burden. In this study, individual symp-
toms were defined as experienced frequently if partici-
pants reported experiencing the symptom ‘several times
a week’ or ‘every day’.
Frailty
Woods et al. demonstrated that a modified version of
the FP, which substituted measures of grip strength and
walking speed for self-report, independently predicted
adverse outcomes, including hospitalisation, disability
and mortality [30]. Studies have since shown that modi-
fied versions of the FP also predict adverse outcomes in
CKD cohorts [31–34]. Delgado et al. demonstrated that
a modified FP was associated with mortality in partici-
pants with non-dialysis dependent CKD [33]. Johansen
et al. determined that a modified FP containing three-
components (specifically weakness/slowness, low phys-
ical activity and “undernourished” with each assigned 1
point) was also associated with mortality in patients re-
ceiving dialysis [31]. Our previous work revealed that
the weight loss FP component is not a significant con-
tributor to HRQOL in patients with CKD, whereas the
exhaustion component is associated with worse scores
across all domains of HRQOL [15]. Bao et al. used a
three-component modified FP that included slowness/
weakness, low physical activity and exhaustion compo-
nents and considered participants with two or more
components as frail [32]. This modified FP was also as-
sociated with mortality in patients receiving dialysis [32].
Comparable to these previous studies, we used a modi-
fied version of the FP comprising three self-report com-
ponents to assess frailty status: 1) weakness/slowness
defined as a SF-12 Physical Functioning score < 75; 2) low
physical activity as ‘inactive’ by the GPPAQ; and 3) ex-
haustion as a SF-12 Vitality score < 55. Each component
was assigned 1 point and a participant was categorised as
frail if two or more components were present.
Statistical methods
As a secondary analysis, no a priori sample size calculation
was performed. All statistical analyses were performed
using IBM SPSS version 25 (IBM, USA). Multiple imput-
ation was performed for data assumed to be either missing
completely at random or missing at random [35]. Missing
ethnicity data and KSQ libido item scores were assumed
to be missing not at random and therefore were not im-
puted. As recommended by Graham et al. [36], the num-
ber of imputations (20 imputations) performed was based
on the fraction of missing information.
Descriptive statistics were used to describe demographic
and clinical characteristics. Pooled mean and standard
error (SE) are reported for imputed continuous variables.
Categorical variables are presented as frequencies and per-
centages. Differences in continuous variables for partici-
pants categorised as non-frail and frail were assessed
using the Independent t test. Multiple linear regression
was used to assess the association between symptom-
burden (KSQ total frequency score) and HRQOL (SF-12
PCS and MCS scores) and frailty status (frail vs. non-frail),
demographics (age and sex) and clinical parameters (eGFR
and haemoglobin). Binomial logistic regression was used
to assess the association between experiencing symptoms
frequently and frailty status (frail vs. non-frail), demo-
graphics (age and sex) and clinical parameters (eGFR and
haemoglobin). Independent variables included in the re-
gression analyses were selected a priori. To minimise the
risk of a type I error, a Bonferroni correction was applied
to an alpha level of 0.05 to determine the level of signifi-
cance for each statistical test.
Principal Component Analysis (PCA) was run on the
KSQ symptom frequency scores to assess the symptom
clusters experienced by participants categorised as non-
frail and frail. PCA was performed on complete cases
only. Only variables with at least one correlation
coefficient ≥ 0.3 in the correlation matrix were included
in the analysis. A minimum overall Kaiser-Meyer-Olkin
(KMO) value of 0.6 and a minimum individual KMO
value of 0.5 were used to determine sampling adequacy.
Bartlett’s test of sphericity was used to indicate that data
was suitable for PCA. An eigenvalue-one criterion was
used to determined how many components to retain.
Furthermore, Varimax rotation was used and symptoms
that loaded on more than one component (using a
minimum coefficient cut-off of 0.5) were removed from
the analysis to create a ‘simple structure’ and aid
interpretability.
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Results
Participant characteristics
Complete data were available to evaluate the frailty sta-
tus of 255 participants out of a total of 353 participants.
Missing data frequency is presented in the Supplemen-
tary Materials File (Table S1). An analysis of complete
cases is also presented in the Supplementary Materials
File (Tables S2, S3, S4 and S5). Following multiple im-
putation, frailty status was calculated for all 353 partici-
pants. Two hundred and twenty-five (64%) participants
were categorised as frail and 128 (36%) participants
categorised as non-frail. Participant demographics and
clinical characteristics are reported in Table 1. Frail par-
ticipants were significantly older and had a lower eGFR,
albumin concentration and estimated VO2 peak than
non-frail participants. Furthermore, frail participants re-
ported more health problems than non-frail participants.
Figure 1 demonstrates the overlap of the modified FP
components for participants categorised as frail.
Symptom-burden and HRQOL in participants with frailty
and CKD
Frail participants reported more symptoms and had a
significantly higher KSQ total symptom score than non-
frail participants (Table 1). In addition, frail participants
had significantly lower SF-12 PCS and MCS scores.
Frailty, when adjusted for age, sex, eGFR and haemoglo-
bin, was associated with higher total symptom score and
Table 1 Participant Baseline Demographic and Clinical Characteristics
Non-Frail (n = 128) Frail (n = 225) Unadjusted
P Value
Age (years), mean (SE) 71.5 (0.9) 77.7 (0.6) < 0.001*
Female, n (%) 70 (55) 130 (58)
Current or ex-smoker, n (%) 57 (45) 125 (56)
University/college qualification, n (%) 43 (34) 57 (25)
Self-reported health problems, n (%)
- Diabetes 13 (10) 45 (20)
- Heart 19 (15) 84 (37)
- Stroke 6 (5) 32 (14)
- Blood vessels or circulation 19 (15) 66 (29)
- Lung or breathing 17 (13) 64 (28)
- Liver 7 (5) 16 (7)
- Joints, bones or muscles 52 (41) 161 (72)
- Mental health 14 (11) 37 (16)
Chronic kidney disease stage, n (%)
- CKD G2 14 (11) 17 (8)
- CKD G3a 87 (68) 123 (55)
- CKD G3b 26 (20) 68 (30)
- CKD G4 1 (1) 17 (8)
Laboratory Variables, mean (SE)
- eGFR (mL/min/1.73m2) 50.9 (0.7) 45.8 (0.7) < 0.001*
- Haemoglobin (g/L) 137.4 (1.7) 132.2 (1.1) 0.01
- Albumin (g/L) 41.4 (0.5) 39.2 (0.4) < 0.001*
Frailty Components, n (%)
- Weakness/slowness 12 (9) 179 (80)
- Exhaustion 41 (32) 208 (92)
- Low physical activity 32 (25) 172 (76)
Slow walking pace, n (%) 11 (9) 130 (58)
VO2 Peak mL/kg/min, mean (SE) 33.9 (6.0) 21.7 (9.1) < 0.001
*
Total symptoms, mean (SE) 6.9 (0.3) 9.2 (0.1) < 0.001*
Total symptom score, mean (SE) 14.6 (0.7) 24.9 (0.6) < 0.001*
SF-12 PCS, mean (SE) 51.8 (0.6) 36.4 (0.7) < 0.001*
SF-12 MCS, mean (SE) 53.8 (0.7) 50.2 (0.7) < 0.001*
Data presented as mean (SE) or frequencies (%). *Remain statistically significant following Bonferroni correction. Estimated VO2 Peak, (peak oxygen uptake). SF-12,
Short Form-12
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lower PCS and MCS scores (Table 2). Moreover, frailty
was associated with a 9-point higher total symptom
score. Lower eGFR was associated with higher total
symptom score and lower PCS score. Older age was as-
sociated with lower PCS score. Female participants had
higher total symptom scores and lower MCS score.
Symptoms experienced frequently by participants with
frailty and CKD
Frail participants reported experiencing all symptoms
more frequently than non-frail participants (Table 3).
The three most often reported symptoms frequently
experienced for both frail and non-frail participants in-
cluded bone/joint pain (frail 69%; non-frail 34%), urinary
frequency (frail 64%; non-frail 50%) and tiredness (frail
61%; non-frail 31%). The greatest differences between
frail and non-frail participants were seen with loss of
muscle strength, bone/joint pain, breathlessness, tired-
ness and cramp/muscle stiffness. Frailty, when adjusted
for age, sex, eGFR and haemoglobin, was associated with
higher odds of frequently experiencing all symptoms, ex-
cept loss of appetite, restless legs and urinary frequency
(Table 4). After applying a Bonferroni correction, lower
eGFR and older age were not associated with higher
odds of frequently experiencing any specific symptom.
Female sex was associated with higher odds of frequently
experiencing sleep disturbance and bone/joint pain.
Fig. 1 Overlap of Modified Frailty Phenotype Components for Participants Categorised as Frail
Table 2 Association Between Frailty, Symptom-Burden and
Health-Related Quality of Life
Unstandardised
β Coefficient
SE Unadjusted P Value
KSQ total frequency score
- Frailty 9.28 1.01 < 0.001*
- Age 0.04 0.05 0.39
- Female 3.69 1.00 < 0.001*
- eGFR −0.15 0.05 0.004*
Haemoglobin 0.03 0.03 0.41
SF-12 PCS score
- Frailty −13.57 1.12 < 0.001*
- Age −0.18 0.06 0.002*
- Female −2.19 1.11 0.05
- eGFR 0.16 0.06 0.007*
- Haemoglobin −0.02 0.03 0.48
SF-12 MCS score
- Frailty −3.85 1.14 0.001*
- Age 0.13 0.06 0.03
- Female −3.80 1.09 < 0.001*
- eGFR 0.07 0.06 0.23
- Haemoglobin 0.01 0.03 0.80
*Remain statistically significant following Bonferroni correction
KSQ Kidney Symptom Questionnaire, SF-12 Short Form-12
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Symptom clusters in non-frail and frail participants with
CKD
The suitability of PCA was assessed prior to analysis as
outlined in the statistical methods section. The overall
KMO for frail and non-frail groups was 0.78 and 0.64,
respectively. The minimum individual KMO for frail and
non-frail groups was 0.69 and 0.59, respectively. Table 5
illustrates the 2 symptom clusters experienced by non-
frail participants and the 3 symptom clusters experi-
enced by frail participants. There were symptom clusters
associated with sleep disturbance and musculoskeletal
symptoms for both non-frail and frail participants. Frail
participants experienced an additional symptom cluster
that included the following symptoms: loss of appetite,
tiredness, feeling cold and poor concentration.
Discussion
To our knowledge, this is the first study to explore
symptom experience and its relationship to frailty status
in patients with CKD. High symptom burden is de-
scribed in patients with CKD, particularly pre-dialysis
and dialysis dependent CKD [14]. Our study demon-
strates that patients with earlier CKD stages also have
high symptom-burden. Both renal function and frailty
status are independently associated with symptom-
burden. However, frailty was associated with a 9.3-point
point higher total symptom score, whereas a decrease of
10 ml/min/1.73m2 in eGFR was only associated with a
1.5-point higher total symptom score. Given the high
symptom-burden reported in participants living with
frailty and CKD, the associated worse HRQOL, particu-
larly physical HRQOL, is unsurprising. Perhaps reflect-
ing an associated decline in functional ability, older age
was associated with a lower SF-12 PCS score. As re-
ported in previous studies, female sex was independently
associated with worse HRQOL [37, 38], specifically
lower SF-12 MCS scores, which corresponds with the
greater symptom-burden reported by female
participants.
Frailty was independently associated with two- to over
five-fold higher odds of experiencing all symptoms fre-
quently, except loss of appetite, restless legs and urinary
frequency. There was over four-fold higher odds of fre-
quently experiencing breathlessness, loss of muscle
strength and cramps/muscle stiffness for participants
categorised as frail. Both non-frail and frail participants
had a symptom-cluster containing symptoms that may
contribute to or be the result of sleep disturbance, in-
cluding restless legs, urinary frequency, poor concentra-
tion and sleep disturbance itself. Furthermore, both non-
frail and frail participants had a symptom-cluster con-
taining musculoskeletal symptoms including cramp/
muscle stiffness and bone/joint pain. These symptoms
are often reported in people with CKD, whether receiv-
ing dialysis or not [10, 14]. However, the clusters de-
scribed in our study are different to other reports in
CKD populations [39–42], which may reflect differences
in participant demographics and characteristics. We re-
port symptom-clusters in earlier stages of CKD with a
mean eGFR of 51 and 46 ml/min/1.73m2 in non-frail
and frail participants, respectively. Symptom-clusters
may evolve as kidney function declines and symptom-
burden increases. Further research is needed on the
stability of symptom-clusters with worsening kidney
function.
To our knowledge, no studies have previously explored
symptom-clusters in patients living with frailty with or
without CKD. Within our study, participants categorised
as frail experienced an additional symptom-cluster com-
prising loss of appetite, tiredness, feeling cold and poor
Table 3 Symptoms Experienced Frequently by Non-Frail and Frail Participants
Non-Frail
(n = 128)
Frail
(n = 225)
Difference in Frail vs. Non-Frail (%)
Loss of muscle strength, n (%) 20 (16) 125 (56) ↑40%
Bone/joint pain, n (%) 44 (34) 155 (69) ↑35%
Breathlessness, n (%) 13 (10) 94 (42) ↑32%
Tiredness, n (%) 40 (31) 137 (61) ↑30%
Cramp/muscle stiffness, n (%) 20 (16) 98 (44) ↑28%
Itching, n (%) 22 (17) 92 (41) ↑24%
Sleep disturbance, n (%) 35 (27) 113 (50) ↑23%
Feeling cold, n (%) 32 (25) 109 (48) ↑23%
Poor concentration, n (%) 11 (9) 61 (27) ↑18%
Urinary frequency, n (%) 64 (50) 145 (64) ↑14%
Restless legs, n (%) 18 (14) 59 (26) ↑12%
Loss of appetite, n (%) 3 (2) 29 (13) ↑11%
Data presented as frequencies (%)
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Table 4 Association Between Frailty and Symptoms Frequently Experienced
SE Unadjusted P Value Odds Ratio 95% CI
Itching
- Frailty 0.31 < 0.001* 3.17 1.72–5.84
- Age 0.02 0.89 1.00 0.97–1.03
- Female 0.28 0.04 0.56 0.32–0.97
- eGFR 0.01 0.48 0.99 0.97–1.02
- Haemoglobin 0.01 0.37 0.99 0.98–1.01
Sleep disturbance
- Frailty 0.29 < 0.001* 2.97 1.68–5.25
- Age 0.01 0.61 0.99 0.97–1.02
- Female 0.27 0.002* 2.34 1.38–3.96
- eGFR 0.01 0.37 0.99 0.96–1.02
- Haemoglobin 0.01 0.05 1.02 1.00–1.04
Loss of appetite
- Frailty 0.79 0.07 4.34 0.91–20.70
- Age 0.03 0.34 1.03 0.97–1.08
- Female 0.48 0.14 2.04 0.80–5.17
- eGFR 0.02 0.05 0.96 0.92–1.00
- Haemoglobin 0.01 0.17 0.98 0.96–1.01
Tiredness
- Frailty 0.28 < 0.001* 3.90 2.25–6.78
- Age 0.01 0.02 0.97 0.94–0.99
- Female 0.26 0.01 1.97 1.17–3.30
- eGFR 0.01 0.07 0.98 0.95–1.00
- Haemoglobin 0.01 0.81 1.00 0.98–1.01
Bone/joint pain
- Frailty 0.26 < 0.001* 3.56 2.14–5.92
- Age 0.01 0.29 1.02 0.99–1.04
- Female 0.26 0.007* 2.03 1.21–3.40
- eGFR 0.01 0.06 0.98 0.95–1.00
- Haemoglobin 0.01 0.72 1.00 0.98–1.01
Poor concentration
- Frailty 0.41 0.001* 3.94 1.75–8.87
- Age 0.02 0.66 1.01 0.97–1.04
- Female 0.33 0.06 1.87 0.98–3.56
- eGFR 0.02 0.48 0.99 0.96–1.02
- Haemoglobin 0.01 0.25 1.01 0.99–1.04
Loss of muscle strength
- Frailty 0.32 < 0.001* 4.94 2.61–9.35
- Age 0.02 0.02 1.04 1.01–1.07
- Female 0.29 0.23 1.42 0.80–2.51
- eGFR 0.02 0.04 0.97 0.94–1.00
- Haemoglobin 0.01 0.57 1.01 0.99–1.02
Breathlessness
- Frailty 0.40 < 0.001* 5.65 2.56–12.48
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concentration. These symptoms may be a consequence
of the frailty syndrome itself and were therefore termed
the ‘frailty’ symptom-cluster. Weight loss is a component
of the original FP and likely the result of chronic under-
nutrition and progressive sarcopenia [2, 3, 9]. Self-
reported exhaustion is also a component of the FP [3].
Our previous work demonstrated that it is the most im-
portant FP component contributing to HRQOL in pa-
tients living with frailty and CKD [15]. In this latest
study, frail participants had a lower estimated VO2 peak
than non-frail participants, which may be linked to
symptoms of exhaustion or tiredness [3]. The symptom-
cluster analysis findings highlight that symptom experi-
ence may not be uniform in CKD populations. Holistic
assessment, particularly for individuals identified as frail,
may aid the identification of problematic symptoms.
The Comprehensive Geriatric Assessment (CGA) is
the gold standard of care of the older patient living with
frailty [43]. It is ‘a multidimensional, multidisciplinary
process which identifies medical, social and functional
needs, and the development of an integrated/co-ordi-
nated care plan to meet those needs’ [43]. Frailty is in-
creasingly recognised in specialised medicine, including
nephrology, and the model of care for patients living
with frailty and CKD is evolving [8, 44]. The CGA, or
modified versions, have been successfully used in CKD
populations to identify geriatric impairments and associ-
ated symptoms [44–46].
Most participants within our study had CKD G3, pa-
tients with this degree of renal impairment are usually
managed by healthcare professionals other than nephrol-
ogists, often primary care practitioners. Further research
Table 4 Association Between Frailty and Symptoms Frequently Experienced (Continued)
SE Unadjusted P Value Odds Ratio 95% CI
- Age 0.02 0.29 1.02 0.98–1.05
- Female 0.29 0.27 1.38 0.78–2.43
- eGFR 0.01 0.68 0.99 0.97–1.02
- Haemoglobin 0.01 0.06 0.99 0.97–1.00
Cramp/muscle stiffness
- Frailty 0.34 < 0.001* 4.25 2.19–8.24
- Age 0.02 0.86 1.00 0.97–1.03
- Female 0.29 0.03 1.90 1.07–3.37
- eGFR 0.02 0.26 0.98 0.96–1.01
- Haemoglobin 0.01 0.08 1.02 1.00–1.04
Restless legs
- Frailty 0.35 0.03 2.10 1.06–4.17
- Age 0.02 0.59 1.01 0.98–1.04
- Female 0.31 0.91 1.04 0.57–1.89
- eGFR 0.02 0.78 1.00 0.97–1.04
- Haemoglobin 0.01 0.86 1.00 0.98–1.02
Feeling cold
- Frailty 0.29 0.002* 2.45 1.39–4.31
- Age 0.01 0.59 1.01 0.98–1.03
- Female 0.25 0.15 1.45 0.88–2.38
- eGFR 0.01 0.20 0.98 0.96–1.01
- Haemoglobin 0.01 0.91 1.00 0.98–1.02
Urinary frequency
- Frailty 0.29 0.13 1.54 0.88–2.71
- Age 0.01 0.05 1.03 1.00–1.06
- Female 0.26 0.58 1.15 0.70–1.91
- eGFR 0.01 0.44 0.99 0.96–1.02
- Haemoglobin 0.01 0.30 1.01 0.99–1.02
*Remain statistically significant following Bonferroni correction
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is needed into the most effective approach to imple-
menting the CGA in different care settings, including
primary care [47]. However, this holistic person-centred
approach to care may lead to improved symptom man-
agement and better HRQOL in patients living with
frailty and CKD.
There are acknowledged limitations to this study. The
Physical Functioning and Vitality SF-12 scores were used
within the composite modified FP assessment and within
generation of the SF-12 PCS and MCS scores. This over-
lap may affect the interpretability of the association be-
tween the frailty and HRQOL scores. Furthermore, our
modified FP measure dichotomised participants into
non-frail and frail groups and did not identify pre-frail
individuals who may have been incorporated within the
non-frail group. Frailty measures that have finer granu-
larity, such as the Frailty Index, can more precisely de-
fine risk for any given individual [48]. Regardless, our
modified FP was comparable to that used by other
authors that have demonstrated an association with
outcomes [31–34]. We report a higher prevalence of
frailty than previous studies in non-dialysis CKD popula-
tions [6]. Self-report frailty assessment methods are at
risk of over-estimating frailty status [49]. Nevertheless,
our modified FP was independently associated high
symptom-burden. Furthermore, participants categorised
as frail were older, reported a higher number of health
problems, had lower eGFR, lower albumin concentration
and lower functional ability, all of which are reported in
patients living with frailty [3, 6, 7, 50]. Thus, we consider
our modified FP a pragmatic method to identify patients
at risk of frailty and high symptom-burden. This study’s
cross-sectional design does not allow conclusions to be
made on longitudinal changes in and underlying caus-
ation of symptom experience. It also relied on self-
report and willingness to complete and return a survey
pack. There were associated risks of incomplete survey
return, question misinterpretation, recall bias and sam-
pling bias. Finally, this study involved an older popula-
tion with early stage CKD and did not describe ethnicity,
therefore results may not be generalizable to other pop-
ulations, including those with more advanced CKD.
Conclusions
In conclusion, this secondary analysis has highlighted
that frailty is independently associated with high
symptom-burden and poor HRQOL in people with
CKD. Moreover, people living with frailty and CKD have
a distinctive symptom experience. Proactive interven-
tions are needed that can effectively identify and address
problematic symptoms to mitigate their impact on
HRQOL. We suggest future research evaluates holistic
person-centred models of care for people living with
frailty and CKD.
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